Anavex Life Sciences (AVXL) Net Equity Issued and Repurchased (2010 - 2024)

Anavex Life Sciences (AVXL) has 14 years of Net Equity Issued and Repurchased data on file, last reported at $4.1 million in Q2 2024.

• For the quarter ending Q2 2024, Net Equity Issued and Repurchased fell 51.89% year-over-year to $4.1 million; the trailing twelve-month figure through Sep 2024 stood at $13.8 million (down 15.2% YoY), and the FY2024 full-year result was $11.3 million, down 59.52% from the prior year.
• Net Equity Issued and Repurchased rose to $4.1 million in Q2 2024, from $1.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $91.3 million in Q2 2021 to a low of $254.0 in Q3 2021.
• A 5-year average of $14.7 million and a median of $5.9 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased sank 100.0% in 2021 and surged 41554.98% in 2023, its largest moves.
• Tracing AVXL's Net Equity Issued and Repurchased over 5 years: stood at $26.2 million in 2020, then slumped by 91.19% to $2.3 million in 2021, then sank by 99.88% to $2852.0 in 2022, then surged by 41554.98% to $1.2 million in 2023, then soared by 245.62% to $4.1 million in 2024.
• Business Quant data shows AVXL's Net Equity Issued and Repurchased at $4.1 million in Q2 2024, $1.2 million in Q3 2023, and $8.5 million in Q2 2023.